Patent Act of 1952 -- Patentable Subject Matter -- Ass'n for Molecular Pathology v. Myriad Genetics, Inc.

The article discusses the U.S. Supreme Court's ruling in the 2013 case Ass'n for Molecular Pathology v. Myriad Genetics Inc. which deals with the nation's Patent Act of 1952, patentable subject matter in the U.S., and biotechnology-related innovations. According to the article, the court determined...

Descripción completa

Detalles Bibliográficos
Publicado en:	Harvard Law Review Vol. 127; no. 1; pp. 388 - 408
Formato:	Artículo
Publicado:	Harvard Law Review Association Nov2013
Materias:	Association for Molecular Pathology v. Myriad Genetics Inc. Patentability > Lawsuits & claims Molecules United States. Supreme Court Actions & defenses (Law) Patent law State statutes (United States) Biotechnology laws Law United States
Acceso en línea:	Ver este registro en EBSCOhost

Descripción
Sumario:	The article discusses the U.S. Supreme Court's ruling in the 2013 case Ass'n for Molecular Pathology v. Myriad Genetics Inc. which deals with the nation's Patent Act of 1952, patentable subject matter in the U.S., and biotechnology-related innovations. According to the article, the court determined that molecules which are isolated from native DNA are not patent eligible, but certain molecules that are synthesized in a laboratory can be patented.